Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
about
Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study.In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques.Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 ADCommon Effects of Amnestic Mild Cognitive Impairment on Resting-State Connectivity Across Four Independent Studies.Revolutionizing Alzheimer's disease and clinical trials through biomarkersComplex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunctionThe amyloid hypothesis of Alzheimer's disease at 25 yearsCan physical exercise in old age improve memory and hippocampal function?Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesThree Large-Scale Functional Brain Networks from Resting-State Functional MRI in Subjects with Different Levels of Cognitive ImpairmentBioinformatics Mining and Modeling Methods for the Identification of Disease Mechanisms in Neurodegenerative DisordersBlood-Based Proteomic Biomarkers of Alzheimer's Disease PathologyThe Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's DiseaseFluid Biomarkers in Clinical Trials of Alzheimer's Disease TherapeuticsAutosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical ADRole of HIV in amyloid metabolismRecent advances in the application of metabolomics to Alzheimer's DiseaseCombotherapy and current concepts as well as future strategies for the treatment of Alzheimer's diseaseAdvances in Alzheimer's disease drug developmentThe Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriersThe potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's diseaseMeta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic CriteriaReevaluating Metabolism in Alzheimer's Disease from the Perspective of the Astrocyte-Neuron Lactate Shuttle ModelNetwork dysfunction in Alzheimer's disease: refining the disconnection hypothesisGenetic heterogeneity in Alzheimer disease and implications for treatment strategiesSelf-propagation of pathogenic protein aggregates in neurodegenerative diseasesTherapeutic and diagnostic challenges for frontotemporal dementiaAlternative neural circuitry that might be impaired in the development of Alzheimer diseaseClinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkersHarmonized diagnostic criteria for Alzheimer's disease: recommendationsSynchronizing an aging brain: can entraining circadian clocks by food slow Alzheimer's disease?Neurodegenerative diseases: expanding the prion conceptAmyloid β precursor protein as a molecular target for amyloid β--induced neuronal degeneration in Alzheimer's diseaseUshering in the study and treatment of preclinical Alzheimer diseaseNetwork-based biomarkers in Alzheimer's disease: review and future directionsMild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's diseaseGenetic markers in biological fluids for aging-related major neurocognitive disorderHypertension: a harbinger of stroke and dementiaMetformin promotes tau aggregation and exacerbates abnormal behavior in a mouse model of tauopathyExisting Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation
P2860
Q22001054-46D03C15-E977-434C-AB90-31252AA0E2DBQ22001055-3E7C80E5-FA29-4AF8-AD9E-7ADD57FFE1F5Q22252525-648F1956-169E-4651-B9FF-F809D4FD7049Q24040265-C44B3EEC-B546-4CC5-9591-FBC7744D871CQ26744882-45122B90-9AEC-464B-85B3-C3BD6A882FDCQ26745936-2FF13949-EEA8-4444-8332-E1C67020ACDBQ26749528-D18C6DCB-744F-4B97-9848-B9D5426EDAE7Q26766517-BB2D6E0E-A104-41B1-9AEA-B822487708E9Q26770708-D9E747BC-BEE0-4605-BCAB-ED5544B716B0Q26772021-DA6181D6-B2DB-4418-9674-D1670FB5B021Q26774418-C3453CDB-EE0E-499D-B0E0-0E1E5443C5E3Q26774743-2701403F-AED4-4ACC-9D57-0CFCC51459CEQ26781815-2E310DFD-D452-447B-BB8C-CB24CF959B99Q26784569-9AB5D094-E6D0-4B8E-AFD5-BF33630C7969Q26801666-02F2B715-0566-4750-A9E4-C5CC6C355DB2Q26824179-B463FA9B-9B3C-4AEA-B8AB-C9FF1F0E42B0Q26828606-D4788FC5-372E-42F2-AA1F-779837BEB52BQ26829899-94F6043D-545B-43A0-A100-1FD0033A6F86Q26849352-261B562C-0512-4BD2-B179-BF63E7708BC3Q26849380-8B758332-D2AF-4121-8EA5-85E0D7F01481Q26853347-C4A25F5A-EB01-4DD4-9326-9ECCCB0525BCQ26864063-60B9BA25-8BDB-4812-84AE-513C82EC1E89Q26864926-3DBF5AD2-8640-4529-9A20-D7ECCE35E1FDQ26995432-F48A7ADB-BAA9-40FA-8D03-F7D6B4450064Q26995802-732C8901-94B0-4082-8524-5ABE11682F20Q26996441-6924E08A-7D26-4A45-86DA-248F40F5E9A5Q26998919-0BE36064-8E63-4396-9C49-A10F503A8313Q27001223-4A8FE6D6-4E24-4FE1-B552-F189AD3E5BEEQ27008249-F45E40C1-0025-4997-AFD0-42ADA12EC59FQ27009157-4752036A-6718-4219-AF8E-9E6E6EAD51EDQ27011370-470FBB15-E9DE-4D93-9E7B-A04B93BD7849Q27011744-9F3EA3DD-B90A-4FC4-B113-6E5409AEB5BFQ27012950-DC7F83F5-BA92-4380-986A-1FF7A4EE13C6Q27014791-47017189-B622-4AD2-BA13-3F29ACFE6082Q27023864-2ABA1506-340B-440C-B92E-44D31B2FE8B2Q27027319-5ACA0248-3AB1-44F3-B4E5-288E88E01CF4Q27027348-21928BF3-7A22-4E4C-A1A5-28C4F62AEA3EQ27027494-A5CB63C8-799D-4858-906C-5B93110968A8Q27301246-92942114-7ED9-4823-B200-624A6581A0B8Q27303745-6FB8E6AD-3652-496B-A576-473ABE2582CC
P2860
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@ast
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@en
type
label
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@ast
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@en
prefLabel
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@ast
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@en
P2093
P2860
P50
P3181
P356
P1476
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
@en
P2093
Angela Oliver
Anna Santacruz
Bernardino Ghetti
Chengjie Xiong
Daniel S Marcus
Eric McDade
John M Ringman
Krista Moulder
Nigel J Cairns
Reisa A Sperling
P2860
P304
P3181
P356
10.1056/NEJMOA1202753
P407
P50
P577
2012-07-11T00:00:00Z